1 growth stock that could soar 105%, according to Wall Street experts

Crispr Therapeutics (NASDAQ: CRSP) is a fascinating growth stock that I’ve been watching for a few years now.

In early 2021 it soared to a ridiculous $200, despite the gene-editing biotech having no products or revenue at the time. Fast-forward to today though, I can pick up the stock for just $39.

Importantly, Crispr Therapeutics had its first treatment approved a year ago. Perhaps this is why Wall Street analysts currently have an $80 price target on the stock — 105% higher than the present level!

The lowdown

CRISPR–Cas9 gene editing is a revolutionary technology that allows scientists to precisely modify DNA in organisms to fix mutations and potentially cure diseases.

In late 2023, Crispr Therapeutics and its partner Vertex Pharmaceuticals had the world’s first such therapy approved to treat sickle cell disease and transfusion-dependent beta-thalassemia.

This once-and-done treatment is called Casgevy, and sales will be split 60-40 in favour of Vertex, which is doing most of the commercial heavy lifting.

Despite this historic milestone, the stock has since fallen by 40%. That’s because Casgevy involves the infusion of genetically modified stem cells taken from the patient, and this takes time.

However, some 40 patients had begun to have their cells collected by mid-October. And the two firms see an addressable market of 35,000 patients in Europe and the US, with a further 23,000 in Saudi Arabia and Bahrain.

At a cost of about $2.2m per patient, with a recent plan announced to help US patients on Medicaid afford it, there’s significant revenue growth potential over the next few years.

Indeed, analysts forecast $1bn in revenue in 2027, up from basically nothing today. For context, the company’s market cap is currently a modest $3.5bn.

Risks to consider

Of course, there’s no guarantee that Wall Street targets come to fruition. If the innovative biotech suffers a setback in one of its ongoing clinical trials, the stock could fall sharply, along with brokers’ price targets.

Remember, gene-editing is truly revolutionary because it allows the alteration of the fundamental building blocks of life. Beyond eradicating diseases, it offers the potential to influence traits or even create entirely new organisms.

As Jennifer Doudna, the Nobel Prize-winning co-developer of this technology, wrote: “The power to control our species’ genetic future is awesome and terrifying. Deciding how to handle it may be the biggest challenge we have ever faced.”

Back in 2018, a rogue Chinese scientist used this technology to create the world’s first genetically edited babies that were, he claimed, immune to HIV. Crispr stock dropped around 40% after this bombshell. Something similar could happen again.

Finally, the company is expected to plough all available resources into progressing its pipeline. Therefore, the business is in no way optimised for profits yet. Investing in a loss-making firm obviously adds risk.

I’m bullish

What I like here, though, is the firm’s cash position of $1.9bn in September. That’s a big cushion, especially if Casgevy revenue starts coming in every quarter. It should be enough to fund the drugmaker’s existing pipeline for several years.

Speaking of which, this includes two cancer treatments and a potential functional cure for type 1 diabetes. That could be a big deal one day.

I’m considering buying a few shares later this month.

The post 1 growth stock that could soar 105%, according to Wall Street experts appeared first on The Motley Fool UK.

5 stocks for trying to build wealth after 50

The cost of living crisis shows no signs of slowing… the conflict in the Middle East and Ukraine shows no sign of resolution, while the global economy could be teetering on the brink of recession.

Whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times. Yet despite the stock market’s recent gains, we think many shares still trade at a discount to their true value.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. We believe these stocks could be a great fit for any well-diversified portfolio with the goal of building wealth in your 50’s.

Claim your free copy now

More reading

Ben McPoland has no position in any of the shares mentioned. The Motley Fool UK has recommended CRISPR Therapeutics and Vertex Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.